Generations of studying the root cause of schizophrenia have largely converged around a single theory: the “dopamine hypothesis,” which postulates that a combination of genetic susceptibility, ...

A genetic postmortem analysis of the brains of patients with schizophrenia suggests dysfunction of dopamine receptors in the caudate nucleus may cause the disorder. Investigators identified a ...

Baltimore, Md. (November 1, 2022) – Researchers at the Lieber Institute for Brain Development (LIBD) believe they have solved a riddle that has challenged scientists for more than 70 years: how the ...

Researchers at the Lieber Institute for Brain Development (LIBD) believe they have solved a riddle that has challenged scientists for more than 70 years: how the brain chemical dopamine relates to ...

Among the newer antipsychotic drugs for schizophrenia are a type called dopamine partial agonists. They get this name from the way they work in your brain. You might also hear them called ...

The caudate nucleus (green) is a subcortical brain region located in the striatum. The striatum is one of several neural structures that make up the basal ganglia (colored regions) located below the ...

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach. By Ellen Barry and Christina Jewett The Food and Drug Administration on ...

On Sept. 26, for the first time in nearly 30 years, the U.S. Food and Drug Administration approved a new oral drug, Cobenfy, developed by Bristol Myers Squibb, to treat schizophrenia. Schizophrenia is ...